Addition of Taxanes to Platinum and Fluoropyrimidines in Adjuvant Setting Did Not Improve Survival in Patients with Gastric Cancer after Curative Gastrectomy

Abstract BackgroundTo evaluate whether the addition of taxane to platinum and fluoropyrimidines in adjuvant chemotherapy would result in longer survival than platinum plus fluoropyrimidines in patients who underwent curative gastrectomy.MethodsThis study retrospectively analyzed survival for patients with stage Ⅱ-Ⅲ gastric adenocarcinoma who received curative gastrectomy and adjuvant chemotherapy with platinum plus fluoropyrimidines (PF group) or taxanes and platinum plus fluoropyrimidines (TPF group). Survival curves were estimated using the Kaplan-Meier method, and the differences were compared using the log-rank test.ResultsBaseline characteristics were balanced between the PF group and TPF group. The median disease-free survival (DFS) was 14.9 months (95% CI: 11.0-18.8) in the PF group and 13.8 months (95% CI: 9.3-18.3) in the TPF group (HR=0.90, 95% CI: 0.63-1.29, log-rank test, P=0.560). The median overall survival (OS) was 30.0 months for patients in the PF group (95% CI: 24.5-35.5) and 25.6 months (95% CI: 22.3-28.9) for those in the TPF group (HR=0.93, 95% CI: 0.64-1.35, log-rank test, P=0.705).ConclusionFor stage Ⅱ-Ⅲ gastric adenocarcinoma, the adjuvant triple combination of TPF regimen after curative gastrectomy did not demonstrate survival benefit compared to the PF regimen.